<p>波士頓，2026 年 1 月 8 日（GLOBE NEWSWIRE）——Monte Rosa Therapeutics, Inc.（“Monte Rosa”）（納斯達克：GLUE），一家開發新型分子膠降解劑（MGD）藥物的臨牀階段生物技術公司，今天宣佈以每股 24.00 美元的公開發行價格，定價 11,125,000 股普通股的承銷公開發行，並向某些投資者提供預融資認股權證，以每個預融資認股權證 23.9999 美元的公開發行價格購買 1,375,000 股普通股，這代表每股普通股的公開發行價格減去每個預融資認股權證的 0.0001 美元行使價格。Monte Rosa 還授予承銷商一個 30 天的選擇權，以公開發行價格購買最多 1,875,000 股普通股，扣除承銷折扣和佣金。Monte Rosa 預計此次發行的毛收益約為 3 億美元，未扣除承銷折扣和佣金及發行費用，不包括承銷商購買額外股份的選擇權行使。所有發行的股份和預融資認股權證均由 Monte Rosa 出售。此次發行預計將在 2026 年 1 月 12 日左右完成，具體取決於滿足慣例的交割條件。</p>
<p>Jefferies、TD Cowen 和 Piper Sandler 擔任此次發行的聯合賬簿管理人。Wedbush PacGrow 和 LifeSci Capital 擔任此次發行的被動賬簿管理人。</p>
<p>這些股份和預融資認股權證由 Monte Rosa 根據之前於 2025 年 3 月 20 日向美國證券交易委員會（SEC）提交併於 2025 年 3 月 31 日獲得 SEC 批准的有效貨架註冊聲明進行發行（文件編號：333-285942）。此次發行僅通過書面招股説明書和招股説明書補充進行，這些文件構成註冊聲明的一部分。與此次發行相關並描述其條款的初步招股説明書補充已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上獲取。</p>
<p>與此次發行相關並描述最終條款的最終招股説明書補充將在 SEC 提交，並可在可用時從 Jefferies LLC 獲取，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, 2nd Floor, New York, New York 10022，電話：(877) 821-7388，或通過電子郵件聯繫 Prospectus_Department@Jefferies.com，TD Securities (USA) LLC，地址：c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電子郵件：TDManualrequest@broadridge.com，Piper Sandler &amp; Co.，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，注意：招股説明書部門，電話：(800) 747-3924，或通過電子郵件聯繫 prospectus@psc.com，Wedbush Securities Inc.，注意：ECM 部門，地址：600 Montgomery Street, 29th Floor, San Francisco, CA 94111，或通過電子郵件聯繫 ecm@wedbush.com，或 LifeSci Capital LLC，地址：1700 Broadway, 40th Floor, New York, New York 10019，或通過電子郵件聯繫 compliance@lifescicapital.com。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的出售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格認證。</p>
<p><strong>關於 Monte Rosa</strong></p>
<p>Monte Rosa Therapeutics 是一家臨牀階段的生物技術公司，開發高度選擇性的分子膠降解劑（MGD）藥物，旨在為患有嚴重疾病的患者提供治療。MGD 是小分子蛋白降解劑，具有治療許多其他治療方式（包括其他降解劑）無法治療的疾病的潛力。Monte Rosa 的 QuEEN™（定量和工程化的新底物消除）發現引擎結合了人工智能指導的化學、多樣的化學庫、結構生物學和蛋白質組學，以合理設計具有前所未有選擇性的 MGD。Monte Rosa 開發了行業領先的首創和唯一 MGD 管線，涵蓋自身免疫和炎症疾病、腫瘤學等領域，目前有三個項目在臨牀階段。Monte Rosa 與領先的製藥公司在免疫學、腫瘤學和神經學領域開展持續合作。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含明確和隱含的 “前瞻性聲明”，包括根據 1995 年《私人證券訴訟改革法》及其修訂版的前瞻性聲明，包括但不限於關於 Monte Rosa 對公開發行的時間和完成的預期的隱含和明確聲明，包括與發行相關的慣例交割條件的滿足。前瞻性聲明包括所有非歷史事實的聲明，在某些情況下，可以通過諸如 “可能”、“或許”、“將”、“可以”、“會”、“應該”、“期望”、“打算”、“計劃”、“目標”、“預期”、“相信”、“估計”、“預測”、“潛在”、“繼續”、“正在進行” 或這些術語的否定形式，或其他類似術語來識別關於未來的聲明。</p>
<p>本新聞稿中的任何前瞻性聲明均基於管理層當前的預期和信念，並受到多種風險、不確定性和重要因素的影響，這些因素可能導致實際事件或結果與本新聞稿中所表達或暗示的任何前瞻性聲明存在重大差異，包括但不限於與市場條件相關的不確定性以及與公開發行相關的慣常成交條件的滿足。這些風險和不確定性在 Monte Rosa 最近的 10-K 表格年度報告中的 “風險因素” 部分以及最近的 10-Q 表格季度報告和任何後續向 SEC 提交的文件中有更詳細的描述。此外，任何前瞻性聲明僅代表 Monte Rosa 截至本日期的觀點，不應被視為其在任何後續日期的觀點。Monte Rosa 明確聲明不承擔根據適用法律更新任何前瞻性聲明的義務。對於任何此類前瞻性聲明的準確性，不作任何明示或暗示的陳述或保證。</p>
<p><strong>投資者</strong></p>
<p>Andrew Funderburk</p>
<p>ir@monterosatx.com</p>
<p><strong>媒體</strong></p>
<p>Cory Tromblee, Scient PR</p>
<p>media@monterosatx.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png"/></p>

GLUE

<p>Monte Rosa Therapeutics, Inc. 宣佈了一項 3 億美元的承銷公開發行定價，包括 11,125,000 股普通股，每股定價為 24.00 美元，以及 1,375,000 股預付認股權證，每股定價為 23.9999 美元。該發行預計將於 2026 年 1 月 12 日完成，需滿足慣例條件。Jefferies、TD Cowen 和 Piper Sandler 是聯合賬簿管理人。該發行是在與美國證券交易委員會（SEC）有效的貨架註冊聲明下進行的。Monte Rosa 專注於開發用於治療嚴重疾病的分子膠水降解藥物</p>

<p>BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 11,125,000 shares of its common stock at a public offering price of $24.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,375,000 shares of common stock at a public offering price of $23.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. Monte Rosa also granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Monte Rosa from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares and pre-funded warrants in the offering are to be sold by Monte Rosa. The offering is expected to close on or about January 12, 2026, subject to satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>波士頓，2026 年 1 月 8 日（GLOBE NEWSWIRE）——Monte Rosa Therapeutics, Inc.（“Monte Rosa”）（納斯達克：GLUE），一家開發新型分子膠降解劑（MGD）藥物的臨牀階段生物技術公司，今天宣佈以每股 24.00 美元的公開發行價格，定價 11,125,000 股普通股的承銷公開發行，並向某些投資者提供預融資認股權證，以每個預融資認股權證 23.9999 美元的公開發行價格購買 1,375,000 股普通股，這代表每股普通股的公開發行價格減去每個預融資認股權證的 0.0001 美元行使價格。Monte Rosa 還授予承銷商一個 30 天的選擇權，以公開發行價格購買最多 1,875,000 股普通股，扣除承銷折扣和佣金。Monte Rosa 預計此次發行的毛收益約為 3 億美元，未扣除承銷折扣和佣金及發行費用，不包括承銷商購買額外股份的選擇權行使。所有發行的股份和預融資認股權證均由 Monte Rosa 出售。此次發行預計將在 2026 年 1 月 12 日左右完成，具體取決於滿足慣例的交割條件。</p>
</div><p>Jefferies, TD Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow and LifeSci Capital are acting as passive bookrunners for the offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 Piper Sandler 擔任此次發行的聯合賬簿管理人。Wedbush PacGrow 和 LifeSci Capital 擔任此次發行的被動賬簿管理人。</p>
</div><p>The shares and pre-funded warrants are being offered by Monte Rosa pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on March 20, 2025 and declared effective by the SEC on March 31, 2025 (File No. 333-285942). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>這些股份和預融資認股權證由 Monte Rosa 根據之前於 2025 年 3 月 20 日向美國證券交易委員會（SEC）提交併於 2025 年 3 月 31 日獲得 SEC 批准的有效貨架註冊聲明進行發行（文件編號：333-285942）。此次發行僅通過書面招股説明書和招股説明書補充進行，這些文件構成註冊聲明的一部分。與此次發行相關並描述其條款的初步招股説明書補充已向 SEC 提交，並可在 SEC 網站 www.sec.gov 上獲取。</p>
</div><p>The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email at TDManualrequest@broadridge.com, Piper Sandler &amp; Co., 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com, Wedbush Securities Inc., Attn: ECM Department, 600 Montgomery Street, 29th Floor, San Francisco, CA 94111 or via email at ecm@wedbush.com or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at compliance@lifescicapital.com.</p>
<div class="lb-trans"><p>與此次發行相關並描述最終條款的最終招股説明書補充將在 SEC 提交，並可在可用時從 Jefferies LLC 獲取，注意：股權承銷招股説明書部門，地址：520 Madison Avenue, 2nd Floor, New York, New York 10022，電話：(877) 821-7388，或通過電子郵件聯繫 Prospectus_Department@Jefferies.com，TD Securities (USA) LLC，地址：c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電子郵件：TDManualrequest@broadridge.com，Piper Sandler &amp; Co.，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，注意：招股説明書部門，電話：(800) 747-3924，或通過電子郵件聯繫 prospectus@psc.com，Wedbush Securities Inc.，注意：ECM 部門，地址：600 Montgomery Street, 29th Floor, San Francisco, CA 94111，或通過電子郵件聯繫 ecm@wedbush.com，或 LifeSci Capital LLC，地址：1700 Broadway, 40th Floor, New York, New York 10019，或通過電子郵件聯繫 compliance@lifescicapital.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的出售，除非在任何此類州或司法管轄區的證券法下進行註冊或資格認證。</p>
</div><p><strong>About Monte Rosa</strong></p>
<div class="lb-trans"><p><strong>關於 Monte Rosa</strong></p>
</div><p>Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics 是一家臨牀階段的生物技術公司，開發高度選擇性的分子膠降解劑（MGD）藥物，旨在為患有嚴重疾病的患者提供治療。MGD 是小分子蛋白降解劑，具有治療許多其他治療方式（包括其他降解劑）無法治療的疾病的潛力。Monte Rosa 的 QuEEN™（定量和工程化的新底物消除）發現引擎結合了人工智能指導的化學、多樣的化學庫、結構生物學和蛋白質組學，以合理設計具有前所未有選擇性的 MGD。Monte Rosa 開發了行業領先的首創和唯一 MGD 管線，涵蓋自身免疫和炎症疾病、腫瘤學等領域，目前有三個項目在臨牀階段。Monte Rosa 與領先的製藥公司在免疫學、腫瘤學和神經學領域開展持續合作。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes express and implied “forward-looking statements,” including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Monte Rosa’s expectations regarding the timing and closing of the public offering, including the satisfaction of customary closing conditions related to the offering. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.</p>
<div class="lb-trans"><p>本新聞稿包含明確和隱含的 “前瞻性聲明”，包括根據 1995 年《私人證券訴訟改革法》及其修訂版的前瞻性聲明，包括但不限於關於 Monte Rosa 對公開發行的時間和完成的預期的隱含和明確聲明，包括與發行相關的慣例交割條件的滿足。前瞻性聲明包括所有非歷史事實的聲明，在某些情況下，可以通過諸如 “可能”、“或許”、“將”、“可以”、“會”、“應該”、“期望”、“打算”、“計劃”、“目標”、“預期”、“相信”、“估計”、“預測”、“潛在”、“繼續”、“正在進行” 或這些術語的否定形式，或其他類似術語來識別關於未來的聲明。</p>
</div><p>Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and the risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Monte Rosa’s most recent Annual Report on Form 10-K, as well as the most recent Quarterly Reports on Form 10-Q and any subsequent filings with the SEC. In addition, any forward-looking statements represent Monte Rosa’s views only as of as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Monte Rosa explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿中的任何前瞻性聲明均基於管理層當前的預期和信念，並受到多種風險、不確定性和重要因素的影響，這些因素可能導致實際事件或結果與本新聞稿中所表達或暗示的任何前瞻性聲明存在重大差異，包括但不限於與市場條件相關的不確定性以及與公開發行相關的慣常成交條件的滿足。這些風險和不確定性在 Monte Rosa 最近的 10-K 表格年度報告中的 “風險因素” 部分以及最近的 10-Q 表格季度報告和任何後續向 SEC 提交的文件中有更詳細的描述。此外，任何前瞻性聲明僅代表 Monte Rosa 截至本日期的觀點，不應被視為其在任何後續日期的觀點。Monte Rosa 明確聲明不承擔根據適用法律更新任何前瞻性聲明的義務。對於任何此類前瞻性聲明的準確性，不作任何明示或暗示的陳述或保證。</p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投資者</strong></p>
</div><p>Andrew Funderburk</p>
<div class="lb-trans"><p>Andrew Funderburk</p>
</div><p>ir@monterosatx.com</p>
<div class="lb-trans"><p>ir@monterosatx.com</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒體</strong></p>
</div><p>Cory Tromblee, Scient PR</p>
<div class="lb-trans"><p>Cory Tromblee, Scient PR</p>
</div><p>media@monterosatx.com</p>
<div class="lb-trans"><p>media@monterosatx.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU1qYzJNQ00zTXpVeU56WTVJekl5TURrMU5EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyMjc2MCM3MzUyNzY5IzIyMDk1NDU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Njc5Y2VlN2ItYTkzNC00NGQ4LWE5MWItMDEyOTU4YTljNDM4LTEyMjEwOTgtMjAyNi0wMS0wOS1lbg==/tiny/Monte-Rosa-Therapeutics-Inc-.png"/></p>

Monte Rosa Therapeutics 宣佈 3 億美元承銷公開發行的定價 | GLUE 股票新聞